International Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07536269) titled 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old' on April 10.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Neurocrine Biosciences

Condition: Congenital Adrenal Hyperplasia

Intervention: Drug: Crinecerfont

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 2026

Target Sample Size: 20

To know more, visit https://clinicaltr...